We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Role Of Noninvasive 320-Row Multidetector Computer Tomography

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: July 29, 2011
Last Update Posted: December 5, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Mount Sinai Hospital, Canada
Information provided by (Responsible Party):
University Health Network, Toronto
July 27, 2011
July 29, 2011
December 5, 2016
September 2008
June 2014   (Final data collection date for primary outcome measure)
To assess the coronary luminal stenosis for location, number of vessels involved and severity of luminal stenosis using noninvasive CTCA. [ Time Frame: CTCA 1-2 hours ]
CTCA will be read by a cardiac radiologist blinded to the patients' medical/cardiac history and the results of the stress test. The cardiac radiologist will classify the severity of coronary artery disease according to number of vessels, location and degree of luminal steno-occlusive disease.
Same as current
Complete list of historical versions of study NCT01405690 on ClinicalTrials.gov Archive Site
Perioperative cardiac complications [ Time Frame: In hospital day 0-3, 30 days post surgery and one year ]
Non-fatal and fatal cardiac complications will be reviewed day 0- 3 and day 30 post-surgery and one year. Patients who are discharged home will be contacted by telephone by a research assistant for post-operative follow-up. Non-fatal cardiac complications include myocardial infarction, arrythmias, electrocardiogram ischemic changes, cardiac enzymes elevation, symptoms of congestive heart failure and/or angina
Same as current
Not Provided
Not Provided
The Role Of Noninvasive 320-Row Multidetector Computer Tomography
A Pilot Study: The Role Of Noninvasive 320-Row Multidetector Computer Tomography Coronary Angiogram In Predicting Perioperative Cardiac Complications In Patients Referred For Noncardiac Surgery
Computer tomography coronary angiogram (CTCA) has emerged as a noninvasive alternative to assessing coronary artery luminal disease. Although the use of noninvasive CTCA for the detection of coronary artery disease is on the rise, the current technology of the 64-row multidetector computer tomography (MDCT) is subjected to multiple patient artifacts that can affect image quality.To eliminate these patient related artifacts a more advanced 320-row MDCT was recently developed. The investigators therefore propose that the newly developed 320-MDCT can provide an accurate noninvasive assessment of the severity of coronary artery luminal stenosis as an alternative to an invasive coronary angiogram.

This pilot study consisting of a prospective non-randomized observational trial where a team of surgeon, anesthesiologist, and evaluator are blinded to CTCA results. We hypothesize that the preoperative use of noninvasive computer tomography, with the 320-row MDCT, to visualize the degree of coronary artery stenosis can lead to improved clinical prediction of perioperative cardiac complications.

The 320-row MDCT is based on the 64-row technology with the significant addition of a larger detector capable of scanning the heart within 1 sec or a cardiac cycle, thereby, eliminating patient-related artifacts and may produce higher image quality.13, 14 The scanning time of 5 seconds with the 320-row MDCT is significantly reduced compared to 8-10 seconds for the 64-row MDCT

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
- stable patients undergoing intermediate or high risk elective non-cardiac surgical procedure according to the American Heart Association/American College of Cardiology (AHA/ACC) Guideline for Perioperative Cardiovascular Evaluation for Non-Cardiac Surgery.
Coronary Artery Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2016
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female, 18 years and older
  • Able to understand and willing to sign the Informed Consent Form
  • Undergoing vascular surgery or intermediate risk surgery (these include intraperitoneal, intrathoracic, carotid endarterectomy , head and neck, orthopedics or prostate) AND
  • One or more of the following clinical predictors according to the Revised Cardiac Risk Index:

    1. history of ischemic heart disease (CABG, MI, Stent, positive stress test, Q-waves on ECG)
    2. Diabetes (requiring insulin)
    3. history of congestive heart failure (NYHA I- II)
    4. history of cerebrovascular disease, any of :

      1. history of carotid stenosis
      2. history of ischemic cerebrovascular disease (stroke or TIA)
    5. Aortic or peripheral vascular disease OR
    6. Risk of CAD with 3 or more of the following

      1. Age ≥ 70 years
      2. Hypertension (medicated)
      3. Cholesterol (medicated)
      4. Diabetes (medicated-oral hypoglycemic)
      5. Family history of coronary artery disease

        Exclusion Criteria:

        1. Lack of consent for participation
        2. Pregnancy
        3. History of an allergic response to iodinated contrast medium
        4. History of an allergic response, or other contraindication to beta blockers
        5. eGFR < 45 mL/min
        6. Hemodynamically unstable/compromised
        7. Urgent surgery
        8. Atrial fibrillation > 80 bpm
        9. Uncontrolled tachyarrhythmia
        10. Atrioventricular block (second and third degree)
        11. Moderate to severe aortic stenosis
        12. Not able to hold breath for 5 - 10 seconds
        13. History of multiple myeloma or organ transplant
        14. Severe pulmonary disease including COPD, PAH, asthma
        15. Congestive heart failure presented as NYHA functional class III - IV
        16. Severe anemia
        17. Increased intracranial pressure
        18. Closed angle glaucoma
        19. Absolute contraindication to Nitroglycerin
        20. Presence of medical condition or history that investigator feels would be problematic
        21. Acute myocardial infarction (within 4-6 weeks) -
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
University Health Network, Toronto
University Health Network, Toronto
Mount Sinai Hospital, Canada
Principal Investigator: Eric You Ten Kong, MD PhD FRCPC Mount Sinai Hospital, University Health Network
University Health Network, Toronto
February 2016